BioSig Regains Compliance With All Nasdaq Listing Standards
BioSig Technologies (NASDAQ: BSGM) has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company's common stock price closed above $1.00 for 10 consecutive business days from February 6 to February 17, 2023. Additionally, BioSig received confirmation of compliance with the market value of listed securities, maintaining a value of $35 million or greater for 11 consecutive days from January 31 to February 17, 2023. Both compliance issues have been resolved, according to Nasdaq. BioSig's PURE EP™ System is enhancing signal visualization capabilities in electrophysiology, contributing to improved patient care.
- Regained compliance with Nasdaq minimum bid price requirement.
- Exceeded market value of listed securities requirement for compliance.
- PURE EP™ System demonstrates superior signal visualization capabilities.
- None.
Westport, CT, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, announced today that it has received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq because the bid price of the Company’s common stock closed at or above
In addition, on February 21, 2023, the Company received a second written notice from Nasdaq notifying the Company that compliance with Nasdaq Listing Rule 5550(b) was regained by meeting an alternative compliance standard related to the market value of listed securities (“MVLS”) because the Company’s MVLS had been
About the PURE EP™ System
The PURE EP™ System is a combination of hardware and software that enables the real-time acquisition of raw signal data—absent of unnecessary noise or interference—allowing physicians to make informed clinical decisions based on clear and precise data. With the heightened visualization of active signals, the PURE EP™ System is facilitating personalized patient care and innovations in the field of electrophysiology.
About BioSig Technologies, Inc.
BioSig Technologies is an advanced digital signal processing technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare's biggest priorities — saving time, saving costs, and saving lives.
The Company's first product, the PURE EP™ System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.
The PURE EP™ System is currently in a national commercial launch and an integral part of well-respected healthcare systems, such as Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute. In a blinded clinical study recently published in the Journal of Cardiovascular Electrophysiology, electrophysiologists rated PURE EP™ as equivalent or superior to conventional systems for
The global EP market is projected to reach
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
1 Global Market Insights Inc. March 08, 2022.
FAQ
What is BioSig Technologies' recent compliance status with Nasdaq?
What dates did BioSig Technologies meet the compliance standards?
What is the significance of the PURE EP™ System for BioSig Technologies?
